BofA raised the firm’s price target on PTC Therapeutics (PTCT) to $97 from $96 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid cap biotech earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $75 from $63 at TD Cowen
- PTC Therapeutics assumed with Overweight from Equal Weight at Barclays
- PTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating
- PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook
- PTC Therapeutics sees FY25 product, royalty revenue $823.4M